Journal of Immunology Research / 2013 / Article / Tab 1

Research Article

Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus

Table 1

Patient demographics and disease characteristics of RA before abatacept treatment.

Case numberSexAge (year)Duration of arthritis (month)RF (U/mL)ACPA (U/mL)Erosion on X-ray typical for RATJC (/28)SJC (/28)Patient global VAS (mm)Physician global VAS (mm)DAS28
MMP-3 (ng/mL)Intra-articular
synovitis with PD signals
Teno-synovitis with PD signalsPredni-solone (mg/day)DMARD/
immunosuppressant in combination
Previous DMARD/

6F5710825>100(−)91766736.42160(+)(−)2Cyclosporin AMTX

RA: rheumatoid arthritis; RF: rheumatoid factor; ACPA: anticitrullinated peptide antibody; TJC: tender joint count; SJC: swollen joint count; VAS: visual analogue scale; DAS: Disease Activity Score; ESR: erythrocyte sedimentation rate; MMP: matrix metalloproteinase; PD: power Doppler; SLE: systemic lupus erythematosus; DMARD: disease-modifying antirheumatic drug; F: female; MTX: methotrexate.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.